PellePharm, Inc.

PellePharm, Inc. is focused on developing innovative therapies, particularly patidegib, a topical treatment targeting Gorlin Syndrome and Basal Cell Carcinomas, providing alternatives to existing surgical care options. Founded in 2012 and headquartered in San Francisco, US, PellePharm, Inc. develops groundbreaking dermatological treatments.

The company has engaged in 9 deals, with its most recent funding round occurring on June 28, 2018, raising USD 7. 5 mn. The CEO is Sanuj Ravindran. PellePharm specializes in patidegib, an investigational topical treatment aimed at Gorlin Syndrome and Basal Cell Carcinomas (BCCs).

This product seeks to reduce tumor burden in patients with these rare conditions, providing a non-surgical alternative due to lack of FDA-approved treatments. The company collaborates with organizations like the Gorlin Syndrome Alliance and LEO Pharma to advance its research, targeting the US and Europe for market entry. The revenue model of PellePharm revolves around partnerships and collaborations within the biotechnology sector, involving business-to-business transactions. Revenue generation is expected through milestone payments and royalties from successful clinical trials of patidegib.

The company aims to align with healthcare providers to secure distribution pathways once regulatory approvals are achieved. PellePharm plans to utilize the USD 7. 5 mn raised in July 2018 to expand its product offerings and enter new markets. The company is focused on the upcoming launch of patidegib in the US and Europe, targeting specific patient populations.

This funding will support their strategic initiatives to enhance product development and market access.